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Introduction
The DNA methyltransferase 3A (DNMT3A) gene is mutated in 
approximately 37% of acute myeloid leukemia (AML) patients with 
a normal karyotype (and ~25% of all AML cases) (1) and is also fre-
quently mutated in patients with myelodysplastic syndromes (MDS) 
(2) and T cell leukemias (3). These mutations are almost always het-
erozygous and have been demonstrated to be associated with high 
myeloblast counts, advanced age, and poor prognosis (1, 4–7). In 
addition, these mutations typically occur at variant allele frequen-
cies (VAFs) of approximately 50%, often persist in clinical remis-
sions (8), and return at relapse as part of the founding clone (5, 9). 
Mutations in DNMT3A are by far the most common found in elderly 
people with clonal hematopoiesis of indeterminate potential (CHIP) 
(10–12). All of these data suggest that DNMT3A mutations probably 
represent initiating events for many patients with AML.
In AML patients, DNMT3A mutations are highly enriched for 
changes at a single amino acid in the catalytic domain at position 
R882 (1). Recent studies have shown that the R882H mutation 
leads to an approximately 80% reduction in the methyltransferase 
activity of the DNMT3A enzyme and also exerts a dominant nega-
tive effect on the remaining WT DNMT3A protein present in the 
same cells (13, 14). DNMT3A molecules with the R882H mutation 
form stable heterodimers with WT DNMT3A, which interferes 
with the ability of the WT DNMT3A protein to form active homo-
tetramers and leads to a canonical hypomethylation signature in 
AML samples with R882 DNMT3A mutations (14, 15). In contrast, 
this hypomethylation signature was undetectable in primary AML 
samples with non-R882 DNMT3A mutations, even though these 
mutations are also associated with poor prognosis in AML (1, 14).
About 15%–20% of DNMT3A mutations found in AML are 
single-copy deletions or truncations of DNMT3A resulting from 
nonsense or insertion-deletion frameshift mutations at positions 
other than R882 (1, 16). In MDS patients, 30% of DNMT3A muta-
tions are predicted to cause loss of function (2), but about 60% of 
DNMT3A mutations in people with CHIP have mutations of this 
class (10–12). As noted above, normal karyotype AML patients 
with non-R882 DNMT3A mutations do not have a detectable DNA 
hypomethylation phenotype, suggesting that these mutations gen-
erally do not have dominant negative activity (14). Therefore, we 
hypothesized that the non-R882 mutations in DNMT3A — espe-
cially those that are predicted to cause truncations of DNMT3A 
— may contribute to leukemogenesis through a different mecha-
nism, i.e., haploinsufficiency.
The gene that encodes de novo DNA methyltransferase 3A (DNMT3A) is frequently mutated in acute myeloid leukemia 
genomes. Point mutations at position R882 have been shown to cause a dominant negative loss of DNMT3A methylation 
activity, but 15% of DNMT3A mutations are predicted to produce truncated proteins that could either have dominant negative 
activities or cause loss of function and haploinsufficiency. Here, we demonstrate that 3 of these mutants produce truncated, 
inactive proteins that do not dimerize with WT DNMT3A, strongly supporting the haploinsufficiency hypothesis. We therefore 
evaluated hematopoiesis in mice heterozygous for a constitutive null Dnmt3a mutation. With no other manipulations, 
Dnmt3a+/– mice developed myeloid skewing over time, and their hematopoietic stem/progenitor cells exhibited a long-term 
competitive transplantation advantage. Dnmt3a+/– mice also spontaneously developed transplantable myeloid malignancies 
after a long latent period, and 3 of 12 tumors tested had cooperating mutations in the Ras/MAPK pathway. The residual 
Dnmt3a allele was neither mutated nor downregulated in these tumors. The bone marrow cells of Dnmt3a+/– mice had a 
subtle but statistically significant DNA hypomethylation phenotype that was not associated with gene dysregulation. These 
data demonstrate that haploinsufficiency for Dnmt3a alters hematopoiesis and predisposes mice (and probably humans) to 
myeloid malignancies by a mechanism that is not yet clear.
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onstrated that these mutant alleles were present at VAFs con-
sistent with heterozygosity in nearly all the cells in the samples, 
and RNA-sequencing (RNA-seq) detected expression of all of 
the corresponding transcripts, showing that these 3 mutations 
do not cause nonsense-mediated decay (Supplemental Table 1; 
supplemental material available online with this article; https://
doi.org/10.1172/JCI93041DS1). We performed Western blots for 
DNMT3A on whole cell lysates of primary AML diagnostic bone 
marrow samples possessing these mutations (Figure 1A). Discrete 
bands at the predicted positions of the truncated proteins were 
not detected (despite the detection of full-length DNMT3A in all 3 
samples), suggesting that these mutant proteins may be unstable 
in AML cells. Quantification of these Western blots revealed that 
full-length DNMT3A was reduced in abundance by 52%–63% 
compared with that in a control AML sample that was WT for 
DNMT3A; this also suggests that the residual WT DNMT3A allele 
in these samples must be functional. However, transient expres-
In this study, we define the molecular consequences of 3 trun-
cation mutations and show that they function as null alleles. We 
therefore modeled haploinsufficiency by characterizing hema-
topoiesis in mice heterozygous for a germline null mutation in 
Dnmt3a (17). Our findings suggest that many DNMT3A muta-
tions found in AML patients lead to haploinsufficiency and that 
DNMT3A haploinsufficiency may predispose to myeloid malig-
nancies in both mice and humans.
Results
AML-associated DNMT3A truncation mutations produce an inactive 
DNA methyltransferase. To determine whether AML-associated 
DNMT3A truncation mutations can yield stable proteins that 
can be found in AML cells, we focused on 3 representative muta-
tions first identified in normal karyotype AML patients: Q515*, 
E616fs, and L723fs (1). Whole-genome sequencing of primary 
diagnostic bone marrow samples from these AML patients dem-
Figure 1. Truncated DNMT3A 
proteins are absent in AML cells, 
but stable in HEK293T cells, and 
lack de novo DNA methyltrans-
ferase activity. (A) Western 
blot of endogenous DNMT3A 
(top panel) or actin (bottom 
panel) from primary AML bone 
marrow samples (DNMT3AWT/WT, 
DNMT3AWT/Q515*, DNMT3AWT/E616fs, 
and DNMT3AWT/L723fs). Asterisks 
indicate predicted positions of 
DNMT3A based on correspond-
ing cDNAs (B). (B) Western blot 
of exogenous DNMT3A produced 
by WT, Q515*, E616fs, and L723fs 
DNMT3A cDNAs expressed in 
HEK293T cells. (C) In vitro meth-
ylation of a linearized plasmid 
DNA substrate (pcDNA3.1) by 
recombinant full-length human 
WT or mutant DNMT3A (Q515*, 
E616fs, or L723fs). Time-course 
assays using 1 μg of total protein 
per 35 μl reaction (250 nM). (D) 
In vitro methylation of a linear-
ized plasmid DNA substrate 
(pcDNA3.1) by recombinant 
full-length human WT or 
mutant DNMT3A (Q515*, E616fs, 
or L723fs). Dose response with 
fixed 16-hour incubation. All 
experiments were independently 
performed 3 times, and data for 
C and D are shown as mean ± 
SEM of 3 independent experi-
ments, each performed in trip-
licate. *P < 0.05, 2-way ANOVA 
relative to WT DNMT3A.
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ylation activity, which increased proportionally with reaction time 
(Figure 1C) and enzyme concentration (Figure 1D). In contrast, we 
observed a near total loss of methyltransferase activity with each 
of the 3 truncated DNMT3A forms (Figure 1, C and D).
DNMT3A truncation mutants fail to heterodimerize with WT 
DNMT3A. X-ray crystallography analyses and biochemical stud-
ies of DNMT3A have revealed that its active form is a homotet-
ramer, with 2 interfaces mediating homooligomerization. Both 
of these interfaces are located within the C-terminal catalytic 
methyltransferase domain of DNMT3A: one is a hydrophobic FF 
interface (specifically, F732 and F772), and the other is a polar 
RD interface (specifically, R885 and D876) (18). DNMT3A muta-
tions at residues near these interacting interfaces are common 
in AML patients (e.g., R729, R736, R771, and R882). AML muta-
tions that produce truncated DNMT3A proteins, including Q515*, 
E616fs, and L723fs, remove both of the DNMT3A self-interacting 
interfaces, and therefore we predicted these proteins would fail to 
dimerize with WT DNMT3A.
sion of the cDNAs encoding these mutant forms of DNMT3A did 
yield stable, truncated proteins of the predicted sizes in HEK293T 
cells (Figure 1B), suggesting that these proteins may in fact be 
produced in AML cells and may have potential functional conse-
quences on WT DNMT3A.
To explore the biochemical consequences of these 3 truncat-
ed proteins, we purified human WT, Q515*, E616fs, and L723fs 
DNMT3A using an N-terminal 6x-histidine tag and immobilized 
metal ion (Ni2+) affinity chromatography. Purified recombinant 
proteins were assessed by BCA assays, SYPRO Ruby protein gel 
stains, and quantitative Western blots to validate protein purity 
and abundance. We compared the de novo DNA methyltransfer-
ase activities of WT, Q515*, E616fs, and L723fs DNMT3A using 
an in vitro DNA methylation assay that detects the DNMT3A-
mediated transfer of tritiated methyl groups from the methyl-
donor molecule S-adenosylmethionine (3H-SAM) to a linearized, 
CpG-rich pcDNA3.1 plasmid DNA containing 334 CpG residues in 
the 5.4-kb plasmid. WT DNMT3A exhibited robust de novo meth-
Figure 2. DNMT3A truncation mutants do not heterodimerize with WT DNMT3A and fail to form mutant DNMT3A homodimers. (A) AlphaLISA assay 
schematic of assay for B–E, in which the interaction between DNMT3A-FLAG and DNMT3A-V5 molecules is measured. Anti-FLAG “donor” beads excited 
by light at 680 nm release singlet oxygen, which can excite anti-V5 “acceptor” beads within 200 nm, leading to emission light at 620 nm. (B) AlphaLISA 
measurement of dimerization of WT DNMT3A-V5 with DNMT3A-FLAG (WT, Q515*, E616fs, and L723fs), with crosstitration (4:1, 2:1, 1:1, 1:2, 1:4). (C) Quanti-
fication of DNMT3A-FLAG:DNMT3A-V5 homodimerization (WT:WT, Q515*:Q515*, E616fs:E616fs, and L723fs:L723fs) when mixed at 1:1 stoichiometric ratio. 
(D) Oligomerization of WT DNMT3A-V5 and DNMT3A-FLAG (WT, Q515*, E616fs, or L723fs), mixed at a 1:1 stoichiometric ratio, in response to NaCl. (E) WT 
DNMT3A-V5 and DNMT3A-FLAG (WT, Q515*, E616fs, or L723fs) oligomerization, mixed at a 1:1 stoichiometric ratio, in response to KCl. All data are shown 
as mean ± SD of 3 independent experiments, each performed in triplicate. *P < 0.05, 2-way ANOVA relative to WT:WT.
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forms of DNMT3A were able to produce 
homodimers detectable by this assay (Fig-
ure 2C), indicating that they must exist as 
monomers, essentially ruling out the pos-
sibility that stable mutant/mutant com-
plexes mask the detection of weak WT/
mutant interactions.
Although purified DNMT3A oligomers 
are stable at physiological salt conditions (20), 
optimal de novo DNA methylation occurs 
at low-salt conditions (i.e., <50 mM NaCl or 
KCl) (21, 22). To determine whether low-salt 
conditions favorable for de novo DNA meth-
ylation could facilitate interactions between 
WT and truncated forms of DNMT3A, we 
directly explored the effects of NaCl and KCl 
levels on DNMT3A oligomerization using 
the AlphaLISA assay (Figure 2, D and E). As 
predicted, the WT/WT DNMT3A interaction 
was maximal at low-salt concentrations and 
was inhibited with increasing concentrations 
of NaCl or KCl. The DNMT3A truncations, 
however, exhibited minimal interactions with 
WT DNMT3A, even at very low-salt (e.g., 20 mM) concentrations.
We orthogonally validated the lack of interaction among these 
3 truncated forms of DNMT3A and the WT protein using immu-
noprecipitation assays. We performed low-stringency anti-FLAG 
coimmunoprecipitation assays on FLAG-tagged WT DNMT3A 
mixed with DNMT3A-V5 (WT, Q515*, E616fs, or L723fs). 
Although we could easily detect coimmunoprecipitation of WT 
DNMT3A-V5 from the WT DNMT3A-FLAG pull-down, no trun-
cated DNMT3A-V5 forms were detected in the WT DNMT3A-
FLAG pull-down eluate by Western blotting (Figure 3). This con-
firms the lack of WT/mutant DNMT3A interactions for these 3 
truncation mutations and implies that cells with these mutations 
are essentially haploinsufficient for DNMT3A protein.
Young Dnmt3a+/– mice exhibit normal hematopoiesis. To char-
acterize the effects of Dnmt3a haploinsufficiency on hematopoi-
esis, we used a previously described constitutive Dnmt3a-knock-
out mouse with a neomycin resistance cassette inserted into a 
deletion of exons 18 and 19 of the catalytic domain of Dnmt3a 
(17). We previously verified that this mutation produces a null 
allele with no detectable Dnmt3a protein by Western blotting 
of homozygous null embryos with an N-terminal Dnmt3a anti-
body (23) and determined that the bone marrow cells of these 
homozygous Dnmt3a–/– mice have a focal, canonical DNA hypo-
methylation phenotype using targeted bisulfite sequencing (23). 
In this study, we intercrossed heterozygous Dnmt3a+/– mice on 
To test this hypothesis, we utilized the PerkinElmer AlphaLISA 
amplified luminescence proximity platform (19) to measure direct 
interactions between DNMT3A molecules with or without the 
mutations of interest (Figure 2A). Our approach utilized whole cell 
lysates of HEK293T cells expressing C-terminal epitope-tagged 
(FLAG or V5) WT or mutant DNMT3A, in combination with anti-
FLAG donor and anti-V5 acceptor beads. Upon dimerization of 
FLAG-tagged and V5-tagged proteins and colocalization of their 
corresponding beads, excitation of the donor bead with 680 nm 
light resulted in emission of a quantifiable signal of 620 nm light 
from the acceptor bead.
HEK293T cells were transiently transfected with expres-
sion vectors containing cDNAs for DNMT3A-FLAG (WT, Q515*, 
E616fs, and L723fs) or DNMT3A-V5 (WT), and mixed cell 
lysates were analyzed with the AlphaLISA assay to compare the 
WT/WT interaction with the WT/mutant interactions for Q515*, 
E616fs, and L723fs (Figure 2B). Each of these 3 truncated forms 
of DNMT3A failed to interact with WT DNMT3A when mixed at 
a 1:1 ratio. To detect weak WT/mutant interactions, we altered 
the ratios of DNMT3A proteins in the AlphaLISA assay to drive 
complex formation with a 2- or 4-fold excess of either DNMT3A 
protein component. While the WT/WT DNMT3A interaction 
remained robust across this range of protein ratios, the WT/
mutant interactions were not detectable using any of these 
conditions (Figure 2B). Furthermore, none of these 3 truncated 
Figure 3. DNMT3A truncation mutants do not 
coimmunoprecipitate with WT DNMT3A. Anti-
FLAG immunoprecipitation of WT DNMT3A-
FLAG in HEK293T whole cell lysates mixed with 
HEK293T whole cell lysates with DNMT3A-V5 
(either WT, Q515*, E616fs, or L723fs) or equivalent 
protein from untransfected cells. All experiments 
were independently performed twice.
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Figure 4. Bone marrow cells from Dnmt3a+/– mice display myeloid skewing and a competitive advantage that is time dependent. (A and B) Flow cyto-
metric evaluation of lineage markers from the bone marrow cells of unmanipulated mice harvested at the indicated ages, designated in months (n = 1 per 
genotype per time point). (A) Dnmt3a+/+ mice. (B) Dnmt3a+/– mice. (C–G) Bone marrow from 6-week-old Dnmt3a+/+ or Dnmt3a+/– mice (Ly5.2) was mixed 
50:50 with WT competitor marrow (Ly5.1x5.2) and transplanted into lethally irradiated WT mice (Ly5.1). n = 13 Dnmt3a+/+; n = 10 Dnmt3a+/–. (C) Peripheral 
blood chimerism at 4 months, 6 months, and 1 year after transplant. P < 0.01, 2-sample, 2-tailed t test. (D–G) Percentage of Ly5.2+ cells (i.e., experimental 
cells, either Dnmt3a+/+ or Dnmt3a+/–) in the indicated lineage or progenitor populations at the 1-year time point. *P < 0.05, 1-sample, 2-tailed t test vs. 50% 
corrected for multiple testing by Bonferroni’s method. (D) Peripheral blood–derived cells. (E) Spleen-derived cells. (F and G) Bone marrow–derived cells.
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a C57BL/6 background to generate Dnmt3a+/+, Dnmt3a+/–, and 
Dnmt3a–/– littermates. Mice with all 3 genotypes were born at 
the expected ratios, but the Dnmt3a–/– mice were severely runted 
and died 2 to 3 weeks after birth, as previously described (17). 
Dnmt3a+/– mice did not exhibit a runting phenotype. Using intra-
cellular flow cytometry on stem and progenitor populations, we 
verified that the bone marrow cells of Dnmt3a+/– mice produced 
approximately 50% as much Dnmt3a protein as the cells from 
Dnmt3a+/+ mice in all hematopoietic compartments assessed 
(Supplemental Figure 1). Six-week-old Dnmt3a+/– and Dnmt3a+/+ 
mice were euthanized, and bone marrow was harvested for 
study of mature lineage compartments (myeloid, B, and T cells; 
Supplemental Figure 2A) as well as for myeloid precursors (gran-
ulocyte-macrophage progenitor [GMP], common myeloid pro-
genitor [CMP], and megakaryocyte–erythroid progenitor [MEP] 
cells) and enriched hematopoietic stem cells (HSCs/KLS-SLAM 
cells; Supplemental Figure 2B). At this age, no significant dif-
ferences in the frequencies of any of these compartments were 
observed between Dnmt3a+/+ and Dnmt3a+/– mice.
Loss of 1 copy of Dnmt3a did not lead to an aberrant self-
renewal phenotype when whole bone marrow from these mice 
was serially replated in MethoCult media (Supplemental Fig-
ure 2C). Large cohorts of Dnmt3a+/– (n = 43) and Dnmt3a+/+ mice 
(n = 20) were generated, and peripheral blood counts were evalu-
ated serially; no differences were observed between these geno-
types at any time point up to 1 year of age (data not shown).
Figure 5. Dnmt3a+/– mice develop myeloid malignancies after a long latent period. (A) Kaplan-Meier plot of survival data from littermate-matched 
Dnmt3a+/– (n = 43) and Dnmt3a+/+ (n = 20) mice that were monitored in a 2-year tumor watch. Mice that became moribund were euthanized for pathologic 
analysis. (B) After 2 years, all remaining mice were bled for CBCs and euthanized. All mice were grouped by spleen size into Dnmt3a+/+, clinically unaffected 
Dnmt3a+/–, and affected (moribund) Dnmt3a+/– mice (see Results for details). Affected Dnmt3a+/– mice exhibited anemia and thrombocytopenia, but not 
significant leukocytosis. *P < 0.05; ***P < 0.001, 1-way ANOVA with Bonferroni’s correction for multiple testing. (C) Distribution of pathologic diagnoses 
according to Bethesda criteria for all mice that could be definitively classified (n = 16). (D) Representative histology of tissues from affected Dnmt3a+/– 
mice. Scale bars: 20 μm; 200 μm (low mag).
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Dnmt3a+/– mice gradually develop myeloid skewing, and their 
HSPCs display a competitive advantage that is time dependent. 
Although Dnmt3a+/– mice have normal hematopoiesis at 6 weeks 
of age, serial evaluation of littermate-matched, unmanipulated 
Dnmt3a+/+ versus Dnmt3a+/– mice at 3, 5, 7, and 11 months of age 
revealed a subtle but consistent increase in myeloid lineage cells 
in the bone marrow over time (Figure 4, A and B), with a recip-
rocal decrease in B, T, and erythroid lineage cells. However, the 
progenitor populations from these samples were not significantly 
altered, consistent with the data from 6-week-old mice (Supple-
mental Figure 2 and data not shown). To determine whether the 
hematopoietic stem/progenitor cells (HSPCs) of Dnmt3a+/– mice 
had a competitive advantage over WT cells, we mixed whole bone 
marrow cells from 6-week-old Dnmt3a+/+ or Dnmt3a+/– animals 
(Ly5.2) with equal numbers of competitor WT bone marrow cells 
(Ly5.1x5.2), and transplanted these cells into lethally irradiated 
mice (n = 13 for Dnmt3a+/+ and n = 10 for Dnmt3a+/– mice). There 
was not a significant advantage for Dnmt3a+/–-derived donor cells 
in the peripheral blood at 4 or 6 months after transplant (Figure 
4C). However, when the peripheral blood of these mice was ana-
lyzed at 1 year after transplant, the Dnmt3a+/– donor cells made up 
approximately 80% of all donor-derived cells (Figure 4, C and D). 
We therefore sacrificed all of the mice at this time point to more 
thoroughly define the lineage and progenitor compartments that 
were affected by Dnmt3a haploinsufficiency. We found a signifi-
cant advantage for Dnmt3a+/– cells in both the myeloid and lym-
phoid lineage cells of the spleen and bone marrow (Figure 4, E 
and F). The KLS, MEP, CMP, and GMP compartments from bone 
marrow cells all predominately comprised Dnmt3a+/– -derived 
cells (Figure 4G). Together, these data suggest that absence of 
a single copy of Dnmt3a provides an advantage for HSPCs with 
multilineage potential.
Dnmt3a+/– mice develop myeloid malignancies after a long latent 
period. Because the myeloid skewing and competitive advantage of 
Dnmt3a+/– bone marrow cells was slow to develop, we decided to test 
whether these mice had an increased risk for developing myeloid 
malignancies after a long latent period. We therefore monitored a 
large cohort of unmanipulated, littermate-matched Dnmt3a+/– and 
Dnmt3a+/+ mice for 2 years. After 18 months, several Dnmt3a+/– mice 
(15/43, 35%) became moribund, exhibiting lethargy, abdominal 
distension, ruffled fur, and pale extremities (Figure 5A). Affected 
mice were euthanized and found to have varying degrees of hepa-
tosplenomegaly, with myeloid infiltrates in the spleen, liver, and 
other organs, including the mediastinal and cervical lymph nodes 
(Supplemental Table 2). At the conclusion of the tumor watch at 2 
years, all remaining mice were euthanized for pathologic examina-
tion and an additional 9 Dnmt3a+/– mice were found to have simi-
lar pathologic findings, for an overall penetrance of 24/43 (56%). 
Affected mice were defined as those with spleen sizes greater than 
5 SD above the mean spleen size of Dnmt3a+/+ mice at 2 years of 
age (Figure 5B). In addition to splenomegaly, many Dnmt3a+/– mice 
displayed anemia and thrombocytopenia. Flow cytometry of the 
spleen cells of affected animals revealed positivity for the myeloid 
markers Gr-1 and/or CD11b (Supplemental Table 2). Further, many 
spleens contained sizable populations of cells that coexpressed the 
late myeloid marker Gr-1 and the progenitor marker CD34, one of 
the hallmarks of myeloid leukemias in mice. No cases of myeloid 
malignancy were observed in any of the 20 Dnmt3a+/+ mice dur-
ing the duration of the tumor watch. On the basis of flow cytometry 
and histopathologic evaluation by a blinded, board-certified hema-
topathologist (J.M. Klco), 11 of 16 tumors from the Dnmt3a+/– mice 
were classified by the Bethesda criteria (24) as myeloproliferative 
disease (MPD), 2 were defined as myeloid leukemia with matura-
tion, 2 were called MPD-like myeloid leukemia, and 1 was classified 
as a myeloid sarcoma (Figure 5, C and D, Table 1, and Supplemental 
Table 2). No T cell leukemias were identified.
Transplantable tumors from Dnmt3a+/– mice retain a functional 
WT Dnmt3a allele. Of the 16 Dnmt3a+/– mice with myeloid disease 
that were fully characterized, 6 caused an acute, lethal malig-
nancy when tumors were transplanted into sublethally irradiated, 
WT recipient mice (Figure 6A). Similarly, Poitras et al. (25) noted 
that 6 of 12 tumors arising in Dnmt3afl/+ × Flt3-ITD mice were 
transplantable. The median disease latencies of the transplanted 
tumors from our study ranged from 26 to 90 days (Figure 6A). 
Flow cytometry and gross pathologic examination demonstrated 
that tumors derived from the secondary animals were myeloid 
malignancies that recapitulated the cell surface phenotypes of the 
primary tumors, which all arose in unmanipulated Dnmt3a+/–  mice 
(see Supplemental Figure 3 for a representative example).
Whole-exome sequencing was performed on 3 of the 6 trans-
plantable tumors (tumors A, B, and E) and on tumors from second-
arily transplanted animals to determine whether the residual Dnmt3a 
allele had been inactivated by deletion or mutation. Tumors were 
compared with sorted B220+ B cells from the primary animal’s spleen 
Table 1. Bethesda criteria classification of Dnmt3a+/– tumors
Case Pathologic diagnosis Transplantable? Letter in  
Figure 6A
1 Myeloid proliferation (nonreactive); MPD No N/A
2 Myeloid leukemia with maturation No N/A
3 Myeloid proliferation (nonreactive); MPD No N/A
4 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
No N/A
5 Myeloid leukemia; MPD-like myeloid leukemia Yes A
6 Myeloid leukemia; MPD-like myeloid leukemia Yes D
7 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
Yes B
8 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
Yes E
9 Myeloid leukemia with maturation No N/A
10 Myeloid sarcoma Yes C
11 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
No N/A
12 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
No N/A
13 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
Yes F
14 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
No N/A
15 Myeloid proliferation (nonreactive); 
myeloproliferation (genetic)
No N/A
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Figure 6. Persistent expression of the residual WT Dnmt3a gene in AML samples arising in Dnmt3a+/– mice. (A) Plot demonstrating disease latency for 
sublethally irradiated WT animals engrafted with Dnmt3a+/– tumors, designated A–F (see Table 1 and Supplemental Table 2). For each of the 6 primary 
tumors that were transplanted, 3 to 5 secondary recipient mice were assessed. (B) Copy number variation in sequenced tumors. Note that none of the 
tumors has deletions involving chromosome 12 at the location of the Dnmt3a gene. The locations of 3 cancer-related genes that were amplified (Nras, 
Foxq1) or deleted (Runx1) in tumor E are shown. Tumor E was derived from a male mouse; the single copy of the X chromosome in these tumors “cali-
brates” the color value for a single copy deletion. (C) Representative flow cytometry plots for Dnmt3a protein abundance in the CD11b+ compartment of 
Dnmt3a+/+, Dnmt3a+/–, and Dnmt3a–/– bone marrow samples (top panels) and a WT spleen or Dnmt3a+/– tumors A and B (derived from the unmanipulated 
spleen samples from the primary mice), showing preserved expression of WT Dnmt3a protein in the CD11b+ cells in each tumor spleen sample. The level 
of Dnmt3a protein in the tumor cells was similar to that of the haploinsufficient bone marrow cells. (D) VAFs for selected mutations detected in primary 
tumors (either bulk or sorted to enrich for Gr-1+CD34+ myeloid tumor cells) and in corresponding tumors from transplanted secondary recipients. Kras 
mutation VAFs are from AmpliSeq data (Supplemental Table 6), while other mutation VAFs are from exome sequencing (Supplemental Tables 3–5).
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esis, including the amplification of a segment of chromosome 
3 (containing Nras) and chromosome 13 (containing Foxq1) and 
a deletion of a segment of chromosome 16 (containing Runx1) 
(Figure 6B; see Supplemental Table 7 for a list of potentially rel-
evant genes on copy number–altered intervals).
DNA methylation and expression phenotypes in bone marrow cells 
from Dnmt3a+/– mice. To determine whether nonleukemic Dnmt3a+/– 
bone marrow cells have a DNA methylation and/or gene expression 
phenotype that may contribute to the AML susceptibility phenotype, 
we performed whole-genome bisulfite sequencing and expression 
studies on these cells. Although similar studies have been performed 
on Dnmt3afl/fl HSPCs (29), these studies have not yet been described 
for the germline null mutation in Dnmt3a described by Okano et al. 
(17), either in the heterozygous or homozygous state. We therefore 
harvested total bone marrow cells from unmanipulated, nonleuke-
mic Dnmt3a+/+, Dnmt3a+/–, and Dnmt3a–/– mice and subjected DNA 
from these cells to whole-genome bisulfite sequencing, as previ-
ously described (15). Four independent bone marrow samples were 
evaluated from 2-week-old Dnmt3a+/+ and Dnmt3a–/– mice; previous 
studies in our laboratory revealed that these samples have highly 
similar cellular compositions (23). Samples from 6 time points were 
obtained from Dnmt3a+/– mice, harvested at 2 weeks, 4 weeks (2 
mice), 6 weeks, 3 months, 9 months, or 1 year of age. All animals had 
normal complete blood counts (CBCs) at the time of harvest (data 
not shown). Evaluation of CpG methylation values across the entire 
genome revealed that only a small fraction (3.53%) of all measured 
CpGs were significantly hypomethylated (P < 0.05; see Methods) in 
Dnmt3a–/– bone marrow cells compared with WT cells, whereas only 
0.04% were hypermethylated. Although mean CpG methylation 
was significantly lower in all annotated regions of the genome in the 
Dnmt3a–/– samples, CpG island (CGI) shelves, CGI shores, and gene 
bodies had the most dramatic differences (Figure 7A). Dnmt3a+/– 
samples had far fewer hypomethylated CpGs and were not statisti-
cally different from WT samples at this level of resolution. We plotted 
the distribution of all methylation values across the genome for each 
sample, as shown in Figure 7B. As expected from the analysis above, 
the methylation patterns were highly similar from all sample sets.
We next identified all differentially methylated regions 
(DMRs) between the Dnmt3a+/+ and Dnmt3a–/– samples using 
established methods (15) and passively evaluated these DMRs for 
methylation phenotypes in the Dnmt3a+/– samples. We identified 
7,029 DMRs in the Dnmt3a–/– samples, of which 7,023 (99.9%) 
were hypomethylated (Supplemental Table 8). Then, using this set 
of DMRs, we defined the mean methylation values for the same 
regions in the 6 Dnmt3a+/– samples and found that 1,665 regions 
(23.7% of the total DMRs) were also significantly different in the 
Dnmt3a+/– samples compared with Dnmt3a+/+ samples (Supple-
mental Table 8). Of these 1,665 DMRs, 1,662 (99.8%) were hypo-
methylated in the Dnmt3a+/– samples. A plot of the distribution of 
methylation values from CpGs in DMRs (Figure 7C) revealed both 
the clear-cut hypomethylation phenotype of the Dnmt3a–/– DMRs 
and the subtle but highly consistent hypomethylation phenotype 
of the Dnmt3a+/– DMRs plotted for the same regions.
The canonical nature of the 7,029 DMRs identified in the 
Dnmt3a+/+ versus Dnmt3a–/– samples was revealed in heatmaps that 
display the average methylation value of each DMR as a unique 
data point (Figure 7D). Clearly, nearly all of the DMRs are present 
as the control population. No point mutations or insertion-deletions 
in the residual Dnmt3a allele were detected in any of the tumors 
(Supplemental Tables 3, 4, and 5, and data not shown). A copy num-
ber variation algorithm was employed to detect copy number chang-
es at the Dnmt3a locus. Similarly, when compared with a pooled 
normal control sample, no copy number changes were detected at 
the Dnmt3a locus in any of the sequenced tumors or their deriva-
tives (Figure 6B). Further, intracellular flow cytometry for Dnmt3a 
protein was performed on spleen cells from tumors A and B, which 
demonstrated that Dnmt3a protein expression was maintained in the 
myeloid tumor cells (Figure 6C). The level of protein detected was 
similar to that of CD11b+ cells derived from Dnmt3a+/– mice. These 
data suggest that the residual WT Dnmt3a allele remains functional 
in fully transformed AML tumors arising in Dnmt3a+/– mice.
Exome sequencing revealed potential cooperating muta-
tions in 3 sequenced tumors. Tumor A (classified as AML with 
maturation) contained somatic mutations in the Ras/MAPK 
pathway, including a missense mutation in the tumor suppres-
sor Nf1 (R1414I; tumor A in Figure 6D, and Supplemental Table 
3). In addition, all 4 secondary tumors derived from this primary 
tumor exhibited a canonical activating mutation in Kras (G12C) 
and a canonical activating mutation in Shp2/Ptpn11 (E76K; 
Figure 6D). The Kras and Shp2/Ptpn11 mutations were unde-
tectable in the primary bulk tumor analysis, but were detected 
when the tumor was resorted for Gr-1, CD34 double-positive 
cells to enrich for the myeloid tumor population (Figure 6D), 
suggesting that these mutations were in a different, small sub-
clone. Tumor B also contained a canonical activating mutation 
in Kras (G13D; tumor B in Figure 6D and Supplemental Table 
4). A potentially relevant mutation in the H3K4 methyltrans-
ferase Mll1 (T1311I) was detected in 1 of 2 secondary tumors. 
This mutation was not detected in the original primary tumor 
even after sorting to enrich for myeloid cells, suggesting it may 
have been in a very small subclone in the primary sample or 
acquired during progression in the transplanted animals. The 
secondary samples from tumor B also contained a loss of most 
of chromosome 2 (Figure 6B), which is often associated with 
AML progression in mice (26). To validate the activating Kras 
mutations, we performed targeted sequencing using a PCR-
based approach, followed by sequencing of a 200-bp ampli-
con containing the region encoding amino acids G12 and G13. 
This approach confirmed the Kras mutations in tumors A and B 
and identified an additional tumor with a Kras G12C mutation 
(Supplemental Table 6). These Ras/MAPK pathway mutations 
tended to occur at a higher VAF in the secondary tumors than 
in the unsorted primary tumors (Figure 6D and Supplemental 
Table 6), suggesting that they occurred in subclones that were 
positively selected for when the tumors expanded in secondary 
recipients. Of note, activated Ras mutations have previously 
been detected in tumors arising spontaneously in Dnmt3a-defi-
cient mice (27) and they are known to cooperate with Dnmt3a 
deficiency to cause AML (28). Further, 9 of 52 (17%) AML sam-
ples with DNMT3A mutations from the TCGA study contained 
NRAS or KRAS mutations (16). Finally, although tumor E did 
not have any somatic mutations or insertion-deletions that are 
known to be associated with AML, this tumor had multiple copy 
number alterations that may have been relevant for pathogen-
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cells, but this finding was not corroborated by other probe sets 
from this gene. We also evaluated the expression of all genes that 
were located within 5 kb of a Dnmt3a–/– DMR; none were shown to 
be dysregulated in Dnmt3a+/– KLS cells.
To determine whether Dnmt3a haploinsufficiency altered gene 
expression in a subpopulation of bone marrow cells and/or altered 
the cellular composition of bone marrow, we performed single-cell 
RNA-seq of the total bone marrow cells obtained from a pair of 
5-month-old, littermate-matched, nontransplanted Dnmt3a+/+ and 
Dnmt3a+/– mice (the same 5-month-old samples used in Figure 4, 
A and B). Using the 10× Genomics platform (31), we made cDNA 
libraries from 1,870 cells from the Dnmt3a+/+ marrow and 2,419 cells 
from the Dnmt3a+/– marrow. After normalizing across samples for 
sequencing depth, the aggregated data set contained a mean of 27,232 
reads per cell, a median of 1,478 detected genes per cell, and a medi-
an of 5,180 unique molecular identifier (UMI) counts per cell. Each 
cell was assigned to 1 of 13 hematopoietic cell lineages, as shown in 
the t-SNE plot of Figure 8A, using a reference set of lineage-specific 
gene expression profiles from the Haemopedia database (32). The 
pooled data from the 2 samples revealed all of the expected popula-
tions. However, when the 2 samples were examined independently 
(Figure 8B for Dnmt3a+/+ and Figure 8C for Dnmt3a+/–), an increase 
in the size of the myeloid lineage population was detected in the 
Dnmt3a+/– sample, along with reciprocal decreases in the size of the 
erythroid and B cell populations. The sizes of all identified compart-
ments were compared statistically (Figure 8D), revealing that the 
changes in the sizes of these 3 lineage compartments in the Dnmt3a 
haploinsufficient mice were significant (along with smaller changes 
in other lineages). These data were corroborated by the flow cyto-
metric data shown in Figure 4, A and B. The expression data were 
also clustered using k-means (k = 10). The resulting clusters recapitu-
lated the major cell clusters inferred using the Haemopedia data set 
(Supplemental Figure 6A). We then identified genes whose expres-
sion was specific to each k-means cluster and found that these genes 
are consistent both with expected cell-type markers and the lineage 
assignments (Supplemental Figure 6B). Finally, we examined the 
cells in the myeloid lineage to detect genes that were differentially 
expressed between the Dnmt3a+/+ versus Dnmt3a+/– samples. We 
detected none, in agreement with our observations from the purified 
KLS cells (see Supplemental Table 9 for a comparison of the expres-
sion values for all genes in the myeloid compartment).
Discussion
The most common initiating mutations for normal karyotype AML 
patients occur in the DNMT3A gene (16). The majority of DNMT3A 
mutations in AML patients are heterozygous missense alterations, 
most of which affect amino acid position R882. DNMT3AR882 muta-
tions encode a dominant negative protein that reduces the meth-
yltransferase activity of DNMT3A; as a consequence, these AML 
samples have a focal, canonical hypomethylation phenotype (14, 15). 
However, 15%–20% of AML patients have heterozygous nonsense 
mutations or frameshift insertion-deletions that are predicted to 
result in premature termination of the protein. In this study, we dem-
onstrate that 3 AML-associated truncation mutations in DNMT3A do 
not encode dominant negative proteins, but rather cause haploinsuf-
ficiency for DNMT3A. Mice that are haploinsufficient for Dnmt3a 
in the germline have normal resting hematopoiesis when they are 
in all 4 of the Dnmt3a–/– samples, which were obtained from 4 inde-
pendent mice. We passively plotted the methylation data from the 
6 Dnmt3a+/– samples according to their ages at harvest to determine 
whether the subtle methylation changes in the Dnmt3a+/– were 
age dependent. For this analysis, we focused on the 1,665 DMRs 
that were originally detected in the Dnmt3a+/+ versus Dnmt3a–/– 
samples as well as significantly hypomethylated in the Dnmt3a+/– 
samples (Figure 7E). Clearly, these regions are consistently less 
methylated in all the Dnmt3a+/– samples regardless of the age of 
the mouse at harvest and display intermediate methylation lev-
els compared with Dnmt3a+/+ and Dnmt3a–/– samples (Figure 7F). 
The heatmap suggests that a small subset of CpGs may become 
more hypomethylated with age, but because the differences were 
small, few were statistically significant. Most of the DMRs in both 
the Dnmt3a–/– and Dnmt3a+/– samples mapped to gene bodies and 
intergenic regions (Figure 7G). Very few DMRs were associated 
with promoters or bone marrow–specific enhancer elements (as 
defined by ENCODE) (30). These findings are very similar to those 
found in nonleukemic human hematopoietic cells with heterozy-
gous DNMT3AR882 mutations (15). An example of a typical DMR 
that is hypomethylated in all Dnmt3a–/– samples, but unaffected in 
Dnmt3a+/– samples, is shown in Figure 7H. An example of a DMR 
that is significantly hypomethylated in both the Dnmt3a–/– and the 
Dnmt3a+/– samples is shown in Supplemental Figure 4.
To define expression changes associated with Dnmt3a hap-
loinsufficiency, we purified RNA from KLS cells to provide a uni-
form population of enriched stem/progenitor cells where Dnmt3a 
is normally highly expressed, performed linear amplification and 
labeling, and hybridized all samples with Affymetrix Mouse Exon 
1.0 ST arrays (Dnmt3a+/+ vs. Dnmt3a+/– nontransplanted KLS cells, 
n = 3 each). Comparisons of the average expression values of each 
annotated gene are shown in Supplemental Figure 5. Dnmt3a+/+ 
and Dnmt3a+/– KLS cells had virtually identical expression pat-
terns; only one probe set (from the Clgn gene) was found to be 
significantly different (P < 0.05) between WT and Dnmt3a+/– KLS 
Figure 7. DNA methylation phenotypes of Dnmt3a+/+, Dnmt3a+/–, and 
Dnmt3a–/– mice. (A) Mean CpG methylation levels from whole-genome 
bisulfite sequencing of bone marrow cells from Dnmt3a+/+ (n = 4), Dnmt3a–/– 
(n = 4), and Dnmt3a+/– mice (n = 7). Values for specific annotated regions 
of the genome are shown. Hypothesis testing was performed via 2-tailed, 
pairwise t tests, with Bonferroni’s correction for multiple testing within 
genome regions; **P < 0.01; ***P < 0.001. (B) Density plot of methylation 
values from all CpGs for each bone marrow sample shown in A. (C) Density 
plot of methylation values from 7,029 DMRs defined by comparing the 4 
Dnmt3a+/+ and 4 Dnmt3a–/– samples, all obtained from bone marrow of 
2-week-old mice. Values for the same DMRs were plotted passively for 
Dnmt3a+/– samples. (D) Heatmap showing mean methylation values for the 
7,029 DMRs as defined above. Note that the Dnmt3a+/– samples are plotted 
as a function of the age of the mice at harvest. (E) Heatmap showing mean 
methylation values for the 1,665 DMRs (from the set of 7,029) significantly 
different between Dnmt3a+/+ and Dnmt3a+/– samples. (F) Mean methylation 
values for all 7,029 DMRs from all samples, plotted by genotype from the 
center of the DMRs. (G) Fraction of 7,029 DMRs associated with annotated 
regions of the genome (Dnmt3a–/– DMRs are shown in red, and DMRs also 
significant in Dnmt3a+/– mice are shown in blue). (H) Primary methylation 
values for each CpG (shown as a bar from 0%–100% methylated for each 
sample) in a Dnmt3a–/– hypomethylated DMR inside the Casz1 gene body 
(not significantly hypomethylated in the Dnmt3a+/– samples, P = 0.19 by 
Mann-Whitney U test with Bonferroni’s correction).
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vivo, perhaps akin to that seen in elderly people with CHIP and 
also to that in serially transplanted mice that are fully deficient for 
Dnmt3a (33). Similar observations have been made in mice that 
are haploinsufficient for PU.1/Spi1, where myeloid lineage expan-
sion dramatically increases the probability that a PML-RARA 
transgene will cause APL (26). Together, these observations sug-
gest that loss or inactivation of a single copy of DNMT3A may like-
wise increase the probability of developing AML by expanding the 
pool of myeloid lineage cells that are capable of cooperating with a 
second relevant mutation (e.g., NPMc, FLT3-ITD, etc.).
Normal karyotype AML patients with non-R882 DNMT3A 
mutations have persistent expression of the residual WT DNMT3A 
allele (16), suggesting that the WT copy is neither lost nor down-
regulated with tumor progression. Because biallelic DNMT3A 
mutations are unusual in patients with AML, we asked whether 
the residual WT Dnmt3a allele in tumors arising in Dnmt3a+/– mice 
was likewise intact and functional. With sequencing studies, we 
found no evidence for inactivation of the residual WT allele. Fur-
young; however, they develop myeloid skewing over time, and their 
HSPCs develop a competitive advantage. After about 18 months, 
these mice start to develop spontaneous myeloid malignancies as 
they acquire cooperating mutations. Notably, these malignancies are 
not associated with the loss of the remaining Dnmt3a allele, which 
further supports the predicted haploinsufficiency mechanism. Non-
leukemic bone marrow cells from Dnmt3a haploinsufficient mice 
have a subtle but statistically significant DNA hypomethylation phe-
notype that may contribute to the development of myeloid malig-
nancies by mechanisms that are not yet clear.
DNMT3A mutations are also the most common mutations 
found in the blood cells of elderly individuals with CHIP. How-
ever, in this group of individuals, DNMT3AR882 mutations are 
relatively uncommon (10% of cases), while mutations predicted 
to cause haploinsufficiency are far more common (60% of cases) 
(10–12). Similarly, in this study, we have shown that mice that are 
haploinsufficient for Dnmt3a develop myeloid lineage skewing 
over time and that their HSPCs have a competitive advantage in 
Figure 8. Single cell RNA-seq analysis of bone marrow 
cells from Dnmt3a+/+ versus Dnmt3a+/– mice. (A) t-SNE 
plot colored by inferred cell lineage (the 2 basophils detect-
ed (B) are not labeled). The compartment labeled “Myeloid 
lineage” (J) corresponds to the “Neutrophils” in the Hae-
mopedia database. Each dot represents a single cell. (B) 
t-SNE plot for Dnmt3a+/+ bone marrow cells. Lineages with 
different frequencies from the Dnmt3a+/– cells are circled 
(see C). (C) t-SNE plot for Dnmt3a+/– bone marrow cells. 
Lineages with different frequencies from the Dnmt3a+/+ 
cells are circled (see B). (D) Percentage of cells in each 
sample assigned to each lineage. Statistical significance 
was calculated using Fisher’s exact test with Bonferroni’s 
correction. *P < 0.01; **P < 0.001; ***P < 0.0001.
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The methylation phenotype of AML genomes is dramatically altered 
when progression occurs: CGI hypermethylation, which is normally 
mediated by DNMT3A in AML cells, is attenuated by DNMT3AR882 
mutations, but not in AMLs with haploinsufficiency for DNMT3A 
— probably because the residual WT DNMT3A allele is still active 
(15). In this report, we show for what we believe is the first time that 
nonleukemic, Dnmt3a haploinsufficient bone marrow cells also have 
a hypomethylation phenotype. The alterations in DNA methylation 
are subtle and are not associated with reproducible changes in gene 
expression patterns in either humans or mice, even with comprehen-
sive RNA-seq approaches in human AML samples (15) and single cell 
RNA-seq (this study). Alternative mechanisms have also been shown 
to exist (such as an altered sensitivity of Dnmt3a mutant cells to che-
motherapeutic drugs) (43). However, the downstream consequences 
of loss-of-function mutations in DNMT3A and the mechanisms by 
which they act to initiate AML are unclear at this time. Although new 
approaches will clearly be needed to define these mechanisms, the 
availability of mouse models that accurately recapitulate the conse-
quences of human DNMT3A mutations will greatly facilitate these 
studies in the future.
Methods
Cell culture. HEK293Tc18 cells (ATCC CRL-10852) were cultured in 
DMEM (Gibco; Thermo Fisher Scientific) plus 10% FBS (Atlanta Biologi-
cals) and 1× penicillin/streptomycin (Gibco; Thermo Fisher Scientific).
Protein purification. N-terminal 6xHis-tags (MGSSHHHHHH-
SSGLVPRGSH) and C-terminal V5-tags (GKPIPNPLLGLDST) or 
FLAG-tags (DYKDDDDK) were cloned into a full-length DNMT3A 
(NM_175629.1) expression vector using the pCMV6 (Origene) back-
bone. Missense mutations (Q515*, E616fs, L723fs) in DNMT3A were 
generated using Agilent QuikChange II XL site-directed mutagenesis 
kit by the manufacturer’s protocol (see Table 2 for mutagenesis and 
C-terminal tag cloning primer sequences). Six million HEK293Tc18 
cells (ATCC CRL-10852) were plated per 15-cm plate and transfected 
after 24 hours by standard calcium-phosphate transfection protocols 
ther, we detected Dnmt3a protein in myeloid tumor cells arising 
in Dnmt3a+/– mice, suggesting that these tumors did not progress 
because Dnmt3a function was entirely lost. Our biochemical 
studies of 3 truncation mutations verified that they produce cat-
alytically inactive proteins and that they fail to interact with WT 
DNMT3A. Together, these findings strongly support the hypothe-
sis that truncation mutations must act by causing DNMT3A haplo-
insufficiency and that the residual allele is not inactivated during 
tumor progression in either humans or mice.
The myeloid malignancies that spontaneously developed in 
Dnmt3a+/– mice were often aggressive, with most cases exhibiting 
massive splenomegaly and leukemic infiltrates into various extra-
medullary tissues. While DNMT3A mutations are often found in both 
myeloid and T cell malignancies in humans, we did not detect any 
lymphoid malignancies in the Dnmt3a+/– mice. Since C57BL/6 mice 
have a greater tendency to develop lymphoid versus myeloid malig-
nancies (34–36), haploinsufficiency for Dnmt3a may specifically facil-
itate the development of myeloid tumors. In contrast, the studies of 
mice with the homozygous Dnmt3afl/fl mutation, from Mayle et al. (27), 
Celik et al. (37), and Poitras et al. (25), reported a broader spectrum of 
disease, including myeloid, early thymic progenitor, B cell, and T cell 
malignancies. Therefore, the loss of both copies of Dnmt3a (or domi-
nant negative mutations, such as R882H) may influence the spectrum 
of hematologic malignancies that arise from mutant stem cells.
Recently, 3 other groups (25, 38, 39) have reported models of 
Dnmt3a haploinsufficiency that are associated with hematopoietic 
malignancies. Although all 3 of these studies used a different Dnmt3a 
mutant allele (Tadokoro et al., ref. 40) from the one used here, all 
found evidence that haploinsufficiency may be relevant for tumor ini-
tiation. Meyer et al. (38) and Poitras et al. (25) bred a FLT3-ITD allele 
into Dnmt3a mice with the floxed “Tadokoro” mutation, and both 
noted cooperation to produce AML. Poitras et al. (25) also noted that 
the latency of leukemia development in Dnmt3afl/+ mice was substan-
tially longer than that of the Dnmt3afl/fl mice. Haney et al. (39) evalu-
ated Dnmt3afl/+ mice using a Cre-transgene system (EμSRα-tTA) that 
“leaks” in the germline. Mice with a germline deletion in a 
single Dnmt3a allele were bred into the FVB/N background, 
and approximately 65% developed a chronic lymphocytic 
leukemia–like (CLL-like) phenotype after a long latent peri-
od, whereas 20% developed a nontransplantable myelopro-
liferative phenotype. Inactivating mutations in DNMT3A 
have not yet been described in human CLL patients (41, 42), 
suggesting that the FVB/N background or other factors may 
have contributed to the B cell phenotype. Clearly, all of the 
models have differences in the experimental design that 
could influence their phenotypes and additional experiments 
will be required to fully understand the differences observed 
among these model systems. Regardless, all of these stud-
ies — as well as that described here — support a model where 
Dnmt3a haploinsufficiency provides an initiating “hit” that 
predisposes mice to developing hematologic malignancies.
Is the DNA hypomethylation phenotype associated with 
DNMT3A mutations critical for AML initiation? We have 
recently shown that human patients with DNMT3AR882H 
mutations have a focal, canonical hypomethylation pheno-
type, even in nonleukemic hematopoietic cells (15), similar 
to that of Dnmt3a deficiency in mice (ref. 29 and this study). 
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centrifuged and resuspended at approximately 5,000 cells/μl in PBS 
plus 1× protease inhibitor (Sigma-Aldrich, P8465). Cells were lysed by 
3× snap-freezing in a dry ice/ethanol bath and rapid thawing at 37°C. 
Lysates were clarified by centrifugation at 10,000 g for 10 minutes at 
4°C, and then supernatants were aliquoted and stored at –80°C. To cor-
rect for transfection efficiency and protein stability across lysate sam-
ples, total FLAG- or V5-tagged DNMT3A was assessed via quantitative 
anti-DNMT3A Western blots such that accurate mixing (2:1, 1:1, 1:2, 
etc.) of FLAG- and V5-tagged DNMT3A could be achieved. AlphaLISA 
assays were performed in either 96- or 384-well plates (PerkinElmer 
catalog 6005560 and 6008350). For 96-well assays, lysates were 
diluted in PBS + 1% FBS to 1,000 normalized (see above) cell equiva-
lents/5 μl, and FLAG- and V5-tagged DNMT3A lysates were mixed at 
desired ratios and brought to a final volume of 20 μl (in PBS + 1% FBS) 
with 2,000 total (FLAG-tagged + V5-tagged) normalized cell equiva-
lents. Mixed lysates were incubated for 120 minutes at 4°C in sealed 
PCR tubes, then transferred to the 96-well plates. AlphaLISA anti-FLAG 
donor (PerkinElmer catalog AS103) and anti-V5 acceptor (PerkinElmer 
catalog AL129) beads were mixed in PBS + 1% FBS to make a master-
mix with 40 μg/ml of each bead, and 20 μl of bead master-mix was 
added to each sample in the 96-well plate 15 minutes prior to analysis. 
For 384-well assays, lysates were diluted in PBS + 1% FBS to 250 nor-
malized (see above) cell equivalents/5 μl, and FLAG- and V5-tagged 
DNMT3A lysates were mixed at desired ratios to a final volume of 10 
μl (in PBS + 1% FBS) with 500 total (FLAG-tagged + V5-tagged) nor-
malized cell equivalents. Mixed lysates were incubated for 120 minutes 
at 4°C in sealed PCR tubes, then transferred to the 384-well plates. 
AlphaLISA anti-FLAG donor (PerkinElmer catalog AS103) and anti-V5 
acceptor (PerkinElmer catalog AL129) beads were mixed in PBS + 1% 
FBS to make a master-mix with 60 μg/ml of each bead, and 5 μl of bead 
master-mix was added to each sample in the 384-well plate 15 minutes 
prior to analysis. For assays testing effects of NaCl or KCl on DNMT3A 
oligomerization, PBS + 1% FBS used for dilution of input lysates was 
replaced with 1.06 mM potassium phosphate (monobasic), 2.97 mM 
sodium phosphate (dibasic) pH 7.4 + 1% FBS, with appropriate NaCl or 
KCl required to achieve desired final concentrations. AlphaLISA plates 
were analyzed using a BioTek Synergy 2-plate reader, with a 680/20 nm 
excitation filter and a 620/20 nm emission filter.
Coimmunoprecipitation. Two-hundred-and-fifty-thousand HEK-
293Tc18 cells were plated per well of a 6-well plate and transfected 
after 24 hours by standard calcium-phosphate transfection protocols 
with 2 μg of plasmid DNA. Cellular media was replaced 24 hours after 
transfection, and cells were harvested in PBS by trituration 48 hours 
after transfection. Cells were pelleted by centrifugation at 400 g for 
5 minutes at 4°C and then resuspended at 1 million cells/ml in PBS 
plus 1× protease inhibitor (Sigma-Aldrich, P8465). Cells were lysed by 
3× snap-freezing in a dry ice/ethanol bath and rapid thawing at 37°C. 
Lysates were clarified by centrifugation at 10,000 g for 10 minutes at 
4°C, and supernatants were stored at –80°C. DNMT3A abundance was 
assessed by quantitative Western blotting using 100,000 cell equiva-
lents per sample, allowing effective concentrations of total DNMT3A 
in each lysate to be normalized between conditions. Aliquots of WT 
DNMT3A-FLAG lysates (200,000 cell equivalents) were mixed with 
either an equal abundance of DNMT3A-V5 (either WT, Q515*, E616fs, 
or L723fs) or equivalent protein from untransfected cells and brought to 
a total volume of 600 μl in PBS, mixed with 20 μl prepared anti-FLAG 
M2 magnetic beads (Sigma-Aldrich, M8823), and rotated for 16 hours 
with 25 μg of plasmid DNA. Cellular medium was replaced 24 hours 
after transfection, and cells were harvested in PBS by trituration 48 
hours after transfection. Cells were centrifuged and resuspended at 
approximately 5 million cells/ml in 20 mM sodium phosphate pH 7.65, 
250 mM NaCl, 30 mM imidazole (HisTrap Lysis Buffer) plus 1× pro-
tease inhibitor (Sigma-Aldrich, P8465). Cells were lysed by 3× snap-
freezing in a dry ice/ethanol bath and rapid thawing at 37°C. Lysates 
were clarified by centrifugation at 10,000 g for 10 minutes at 4°C, and 
then supernatants were filtered through a Whatman 25 mm GD/X PES 
5-μm filter before storage at –80°C. Clarified and filtered lysates were 
loaded onto two 1-ml GE HisTrap HP columns (in-series) using a GE 
AKTApurifier with UNICORN software (GE v5.11) running with His-
Trap Lysis Buffer. Loaded HisTrap columns were washed with 10 ml 
of HisTrap Wash Buffer (20 mM sodium phosphate pH 7.65, 500 mM 
NaCl, 35 mM imidazole), and proteins were eluted with HisTrap Elu-
tion Buffer (20 mM sodium phosphate pH 7.65, 250 mM NaCl, 400 
mM imidazole). Protein-containing fractions were then dialyzed into 
DNMT3A Storage Buffer (25 mM Tris-HCl pH 7.65, 100 mM glycine, 
10% glycerol [v/v]) and stored at –80°C. Protein concentrations were 
determined by Pierce BCA Kit (Thermo Fisher Scientific) and validat-
ed by quantitative Western blot; fraction purity was confirmed using 
SYPRO Ruby protein gel stains (Thermo Fisher Scientific).
Western blotting. Protein samples were separated by SDS-PAGE 
using NuPAGE (Thermo Fisher Scientific) gels and transferred to 
nitrocellulose membranes (GE Amersham). Membranes were blocked 
with Western blocking solution (5% nonfat dry milk in Tris-buffered 
saline with Tween-20 [TBST]) for at least 1 hour at room temperature 
or at 4°C for 16 hours, then probed with primary antibodies in Western 
blocking solution for either 2 hours at room temperature or 16 hours 
at 4°C. Membranes were rinsed 3 times in TBST and then incubated 
with horseradish-peroxidase–conjugated anti-rabbit (1:5000; GE 
NA9340V) or anti-mouse (1:5000; GE NXA931) secondary antibodies 
for 1 hour at room temperature. Membranes were then washed 5 times 
in TBST, after which ECL (Bio-Rad Clarity Western ECL) was applied 
according to the manufacturer’s protocols; then membranes were 
imaged with a Thermo Fisher Scientific myECL Imager. The primary 
antibodies used were as follows: anti-DNMT3A (1:2000, Cell Signal-
ing Technology, D23G1/3598), anti-FLAG (1:2000, Sigma-Aldrich, 
F1804), and anti-V5 (1:2000, Thermo Fisher Scientific, R960-25).
In vitro methylation. In vitro methylation reactions were performed 
on EcoRI-linearized pcDNA3.1+ vector (Thermo Fisher Scientific, V790-
20). Reactions were carried out in 35 μl at 37°C, including 20 mM HEPES 
pH 7.65, 30 mM NaCl, 0.5 mM DTT, 1 mM EDTA, 0.2 mg/ml BSA, and 
5 μM 3H-labeled SAM (Perkin-Elmer) plus DNA substrate and purified 
recombinant DNMT3A enzyme. To stop the reactions, they were added 
to 35 μg tRNA carrier (Sigma-Aldrich) in borosilicate tubes on ice, then 
quenched with 100-fold ice-cold 10% TCA. DNA was allowed to pre-
cipitate for 10 minutes. Samples were then spotted onto Whatman GF/C 
25-mm filters on a 30-well multi-plater, and washed with 2 ml ice-cold 
10% TCA, then 2 ml of 95% ethanol once, after which they were dried 
and measured using a scintillation counter.
AlphaLISA assays. Two-and-a-half million HEK293Tc18 cells were 
plated per 10-cm plate and transfected after 24 hours by standard 
calcium-phosphate transfection protocols with 8 μg of plasmid DNA 
(expression vectors from above with C-terminal V5- or FLAG-tags). Cel-
lular medium was replaced 24 hours after transfection, and cells were 
harvested in PBS by trituration 48 hours after transfection. Cells were 
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ments, mice were monitored daily and animals displaying signs of 
illness (lethargy, hunched posture, ruffled fur, dyspnea, or pallor) 
were euthanized and spleen and bone marrow harvested for analysis. 
Diagnosis of leukemia was made by light microscopic examination of 
spleen and/or peripheral blood cells according to the Bethesda criteria. 
Cytospin tissue slides were stained with Wright-Giemsa stain (Sigma-
Aldrich) and were imaged using a Nikon MICROPHOT-SA microscope 
equipped with an oil-immersion ×50/0.90 or ×100/1.30 objective lens 
(Nikon Corp.). The tumor watch was terminated after 2 years.
Methylcellulose colony formation assay. Ten thousand cells per plate 
were plated in triplicate in M3534 MethoCult media containing IL-3, 
IL-6, and stem cell factor (SCF) (Stem Cell Technologies) and incubated 
at 37°C for 1 week. Each week, clusters of cells meeting the morpholog-
ic criteria for CFU-GEMM, CFU-GM, CFU-G, or CFU-M (http://www.
stemcell.com/~/media/Technical%20Resources/8/3/E/9/0/28405_
methocult%20M.pdf?la=en) were counted as myeloid colonies and 
cells were lifted using warm DMEM media + 2% FBS, spun down, and 
replated as before. An aliquot of cells was taken for analysis of myeloid 
markers by flow cytometry.
Cell staining and flow cytometry. After ACK lysis of red blood cells, 
peripheral blood, bone marrow, or spleen cells were treated with anti-
mouse CD16/32 (clone 93, eBioscience) and stained with the indicat-
ed combinations of the following antibodies (all antibodies are from 
eBioscience unless indicated): CD34 FITC (clone RAM34), CD11b PE 
or APC-e780 (clone M1/70), c-kit PerCP-Cy5.5 or APC-e780 (clone 
2B8), CD115 APC or PE (clone AFS98), Gr-1 Pacific blue (Invitrogen, 
clone RM3028), Gr-1 biotin (clone RB6-8C5), B220 PE, APC, or biotin 
(clone RA3-6B2), CD3 e450 or PE (clone 145-2C11), CD71 PE(clone 
R17217), Ter-119 Pacific blue (clone TER-119), CD16/32 APC (clone 
93), Flk2 APC (clone A2F10), CD150 PE (BioLegend 115903, clone 
TC15-12F12.2), Ly5.1 PE or FITC (clone A20), Ly 5.2 APC or e450 
(clone 104), and streptavidin 605 NC (clone 93-4317-42). The fol-
lowing flow phenotypes were used for stem and progenitor cell flow: 
Lin– (lineage negative): B220–, CD3e–, Gr-1–, Ter-119–; KLS: Lin–, Sca-
1+, c-Kit+; KLS-SLAM: Lin–, Sca-1+, c-Kit+, CD150+; LT-HSC: Lin–, 
Sca-1+, c-Kit+, CD34–, Flk2–; MPP: Lin–, Sca-1+, c-Kit+, CD34+; GMP: 
Lin–, Sca-1–, c-Kit+, CD34+, CD16/32+; CMP: Lin–, Sca-1–, c-Kit+, CD34+, 
CD16/32–; and MEP: Lin–, Sca-1–, c-Kit+, CD34–, CD16/32–. Analysis 
was performed using a FACScan (Beckman Coulter) or I-Cyt Synergy 
II Aorter (I-Cyt Technologies) and data analyzed using FlowJo (Tree 
Star), Excel (Microsoft), and Prism 5 (GraphPad).
Single cell RNA-seq. cDNA libraries were prepared from individual 
cells using the Chromium Single Cell 3′ Solution from 10× Genom-
ics (including the Chromium Single Cell 3′ Chip Kit v2 [PN-120236], 
Library & Gel Bead Kit v2 [PN-120237], and Chromium i7 Multiplex 
Kit [PN-120262]), according to the instructions in the Chromium 
Single Cell 3′ Reagent Kits v2 User Guide, Rev A (31). cDNA libraries 
were sequenced on the Illumina HiSeq 25001T in Rapid Run mode. 
All analyses were performed using R 3.3.1 and Cell Ranger 1.3.1. Cell 
Ranger was used to demultiplex and align the sequencing reads, cor-
rect and count the UMIs for each gene in each cell, normalize the 
data to account for differences in sequencing depth across samples, 
exclude genes with 0 UMI counts, and normalize each cell to the medi-
an (using normalize_barcode_sums_to_median). We assigned each 
cell in the data set to one of 13 hematopoietic lineages by training a 
k-Nearest Neighbors algorithm on expression data from Haemopedia 
(http://haemosphere.org/), an atlas of microarray expression data for 
at 4°C. After immunoprecipitation, the beads were washed 3× with 1 ml 
PBS with 1× protease inhibitor cocktail, and proteins were eluted with 
0.1 M glycine HCl, pH 3.0. Western blot bands at approximately 64 kD 
and 26 kD represent coelution of heavy and light chains of immunopre-
cipitation IgG, recognized by Western blot secondary antibody.
Primary AML samples. All cryopreserved primary AML samples 
(TCGA ID nos. 2839, 2851, 2879, 2993) were collected. Primary AML 
cells from bone marrow (cryopreserved in 10% DMSO) were quickly 
thawed in the presence of a 1× protease inhibitor cocktail (Sigma-
Aldrich, P8465) and 1 mM PMSF (Sigma-Aldrich, 10837091001) 
resuspended in 10 ml of PBS with 20% FBS with 1× protease inhibitor 
cocktail and 1 mM PMSF and centrifuged at 400 g for 5 minutes at 4°C. 
Cells were lysed for 10 minutes on ice, at 5 million per 100 μl, in ice-
cold RIPA buffer (Thermo Fisher Scientific, 89900) with 1× protease 
inhibitor cocktail and 1 mM PMSF. Lysates were centrifuged at 10,000 
g for 5 minutes at 4°C, and supernatants were collected and stored at 
–80°C after quantification by BCA assay. Western blots of primary sam-
ples were performed with 120 μg total protein per sample for DNMT3A 
detection and 1 μg total protein per sample for actin detection.
Mice. Dnmt3a+/– mice (17) were obtained from the Mutant 
Mouse Regional Resource Centers repository (MMRRC Strain Name 
B5.129S4-Dnmt3atm2Enl/Mmnc) and were backcrossed for more than 
10 generations in the B6 strain prior to use in these studies. Whenever 
possible, littermate controls were used for all experiments.
Bone marrow harvest and transplantation. Bone marrow was har-
vested from femurs, tibias, pelvi, and humeri of mice. After lysis of 
red blood cells (ACK buffer: 0.15 M NH4Cl, 10 mM KHCO3, 0.1 mM 
Na2EDTA), cells were washed with FACS buffer, filtered through 
50-μm cell strainers (Partek), and resuspended in PBS at 1 million 
cells/100 μl for transplantation. For competitive transplant experi-
ments, bone marrow was mixed 50:50 with freshly harvested cells 
from 6-week-old Ly5.1x5.2 mice (The Jackson Laboratory). Trans-
plantation was performed by retroorbital injection of 1 × 106 total 
bone marrow cells into lethally irradiated Ly5.1 recipients that had 
received 2 split doses of 550 cGy total body irradiation spaced at 4 
hours (Mark 1 Cesium-137 irradiator, JL Shepherd) 24 hours prior to 
transplantation. For tumor transplants, recipient Ly5.1 mice were 
sublethally irradiated (600 cGy) and retroorbitally injected with 1 
million tumor cells.
Intracellular DNMT3A staining. Intracellular DNMT3A was detect-
ed with the BD Biosciences — Pharmingen Transcription Factor Buffer 
Set 562574 according to the manufacturer’s instructions. Briefly, bone 
marrow cells were isolated from femurs and tibias and lysed with red 
cell lysis buffer. Cells were stained with cell-surface markers to identify 
cell type by flow cytometry and then fixed for 40 minutes at 4°C. Cells 
were washed with perm wash buffer and incubated with primary anti-
body against DNMT3A (1:400 dilution, D23G1, Cell Signaling Technol-
ogy) for 30 minutes at 4°C. Cells were rinsed in perm wash buffer and 
incubated in secondary antibody (1:500 dilution, chicken anti-rabbit 
Alexa Fluor 647, Molecular Probes) for 30 minutes at 4°C. Cells were 
rinsed in perm wash buffer and analyzed by flow cytometry. The mean 
fluorescence intensity was calculated for the AF647 signal, and values 
were normalized against the values of each bone marrow compartment 
for the first Dnmt3a+/+ mouse in each experiment set.
Mouse analysis and tumor watch. Peripheral blood counts were 
assessed at regular intervals, as indicated, by automated CBC (Hema-
vet 950, Drew Scientific Group). For long-term tumor watch experi-
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from the Covaris plate and dispensed into a 96-well Bio-Rad Cycle 
plate by a CyBio-SELMA instrument. Small insert dual indexed Illu-
mina paired-end libraries were constructed with the KAPA HTP Sam-
ple Prep Kit (KAPA Biosystems) on the SciClone instrument (Perki-
nElmer) according to the manufacturers’ recommendations. Dual 
indexed adaptors were incorporated during ligation; the same 8-bp 
index sequence is embedded within both arms of the library adaptor. 
Libraries were enriched with a single PCR reaction for 8 cycles. The 
final size selection of the library was achieved by a single AMPure XP 
Paramagnetic Bead (Agencourt, Beckman Coulter Genomics) cleanup 
targeting a final library size of 300 to 500 bp. The libraries underwent 
a qualitative (final size distribution) and quantitative assay using the 
HT DNA Hi Sens Dual Protocol Assay with the HT DNA 1K/12K chip 
on the LabChip GX instrument (PerkinElmer). Libraries were captured 
using the Nimblegen SeqCap EZ Library Reagent. The final concentra-
tion of each capture pool was verified through qPCR utilizing the KAPA 
Library Quantification Kit — Illumina/LightCycler 480 kit according 
to the manufacturer’s protocol (Kapa Biosystems) to produce cluster 
counts appropriate for the Illumina HiSeq2000 platform. Each capture 
pool was loaded on the HiSeq2000 version 3 flow cell according to the 
manufacturer’s recommendations (Illumina). For each sample, 2 × 101 
bp read pairs were generated, yielding approximately 7 to 25 Gb of data 
per tumor sample and 4 to 16 Gb per normal sample. Data were depos-
ited into the NCBI’s SRA (BioProject PRJNA392335).
Variant detection pipeline. Sequence data were aligned to mouse 
reference sequence mm9 (with the OSK vector sequence added) 
using bwa version 0.5.9 (47) (parameters: -t 4 -q 5::). Bam files were 
deduplicated using picard version 1.46. Single nucleotide variants 
(SNVs) were detected using the union of 3 callers: (a) samtools ver-
sion r963 (48) (parameters: -A -B) intersected with Somatic Sniper 
version 1.0.2 (49) (parameters: -F vcf -q 1 -Q 15) and processed 
through false-positive filter v1 (parameters: --bam-readcount-ver-
sion 0.4 --bam-readcount-min-base-quality 15 --min-mapping-qual-
ity 40 --min-somatic-score 40) (b) VarScan version 2.2.6 (50) filtered 
by varscan-high-confidence filter version v1 and processed through 
false-positive filter v1 (parameters: --bam-readcount-version 0.4 
--bam-readcount-min-base-quality 15 --min-mapping-quality 40 
--min-somatic-score 40), and (c) Strelka version 0.4.6.2 (51) (param-
eters: isSkipDepthFilters = 1). Indels were detected using the union of 
4 callers: (a) GATK somatic-indel version 5336 (52) filtered by false-
indel version v1 (parameters: --bam-readcount-version 0.4 --bam-
readcount-min-base-quality 15), (b) pindel version 0.5 (53) filtered 
with pindel false-positive and vaf filters (parameters: --variant-freq-
cutoff=0.08), (c) VarScan version 2.2.6 (50) [filtered by varscan-high-
confidence-indel version v1 then false-indel version v1 (parameters: 
--bam-readcount-version 0.4 --bam-readcount-min-base-quality 
15), and (d) Strelka version 0.4.6.2 (51) (parameters: isSkipDepthFil-
ters = 1). Variants were filtered using a Bayesian classifier (https://
github.com/genome/genome/blob/master/lib/perl/Genome/ 
Model/Tools/Validation/IdentifyOutliers.pm), retaining variants 
classified as somatic with a binomial log-likelihood of at least 5. 
Manual review also resulted in the removal of all variants in the 
region chr1:90,100,000–151,800,000, which appeared to be arti-
facts. Putative variants that differed significantly from the expected 
homozygous or heterozygous ratios were removed using an R script 
(https://raw.githubusercontent.com/genome/genome/master/lib/
perl/Genome/Model/Tools/Analysis/RemoveContaminatingVar
54 murine cell types, spanning all mature hematopoietic cell lineages 
and several progenitor populations (32). Specifically, we constructed 
a reference matrix of expression profiles, where each column repre-
sents one of the 54 cell types and each row represents one of 2,978 
lineage-specific genes (32). We extracted single-cell RNA-seq data for 
the 2,353 lineage-specific genes that are measurably expressed in our 
data. We calculated Spearman correlations between the cells from 
our single-cell data sets and each cell type in the reference matrix, 
ranked the reference cell types by correlation, and chose the top 3. We 
assigned a cell to a lineage if at least 2 of the top 3 reference cell types 
belonged to that lineage. Cells with fewer than 200 measured genes 
were not assigned a lineage. Fisher’s exact test (with Bonferroni’s 
correction) was used to compare the proportion of cells assigned to 
a given lineage in each sample. Using Cell Ranger 1.3.1, median-nor-
malized expression data were clustered using the k-means algorithm 
(k = 10). Cluster-specific (or sample-specific) genes were identified 
by applying the “sseq” differential expression method to the unnor-
malized data, and by requiring a fold-change of at least 2 between the 
clusters (samples). t-SNE plots were created using Cell Ranger 1.3.1. 
Data were deposited into the NCBI’s Sequence Read Archive (SRA 
BioProject PRJNA392335).
Whole-genome bisulfite sequencing and analysis. Bisulfite sequenc-
ing was performed using whole-genome bisulfite-converted sequenc-
ing libraries generated with the Epigenome library preparation kit. 
DNA was isolated using a QiaAmp DNA Mini Kit (QIAGEN 51304). 
Input DNA (200 ng) from each sample was bisulfite converted using 
the DNA Methylation Gold Kit (Zymo Research). The converted sin-
gle-stranded DNA (ssDNA) was eluted into 27 μl. Each sample under-
went 4 individual library preps, 9 μl/library prep, using the EpiGnome 
TruSeq DNA Methylation Kit (Illumina EGMK81312). Library prep 
was completed per the manufacturer’s protocol. After library prep, all 
4 reactions for each sample were pooled and quantified by dsDNA HS 
Qubit (Life Technologies Q32851) and sized with the High Sensitivity 
DNA Chip Kit (Agilent 5067-4626). Samples were assayed by quanti-
tative PCR (qPCR), and on the basis of qPCR results, diluted to a 2 nM 
solution. Indexed sequencing was performed on Illumina HiSeq 2000 
or 25001T instruments and reads were mapped with BSMap (version 
1.037) using default parameters (44). Methylation ratios were obtained 
using the methratio.py script. The program “metilene” (45) was used 
to analyze the raw methylation ratios at all CpGs to identify DMRs 
with more than 10 CpGs and a mean methylation difference between 
the same groups of more than 0.2. DMRs were filtered to retain those 
with an FDR of less than 0.05, and adjacent DMRs less than 50 bp 
apart were merged. Following these procedures, methylation data 
from individual CpGs were imported into R as bsseq objects (46) for 
manipulation and analysis, which included “smoothing” using the 
BSmooth function with the parameters ns = 35 and h = 500 to impute 
missing methylation values for visualization; all statistical procedures 
and analysis used raw methylation ratios (or methylation counts) from 
individual CpGs or summed data for DMRs. Data were deposited into 
NCBI’s SRA (BioProject PRJNA392335).
Illumina library construction and exome sequencing. Genomic DNA 
from all tumor samples and/or matched normal samples were frag-
mented using a Covaris LE220 DNA Sonicator (Covaris) within a size 
range between 100 and 400 bp using the following settings: volume 
= 50 μl, temperature = 4°C, duty cycle = 20, intensity = 5, cycle burst 
= 500, time = 120 seconds. The fragmented samples were transferred 
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Supplemental tables. Supplemental Table 1 shows DNA and RNA 
VAFs for DNMT3A truncation mutants. Supplemental Table 2 shows 
detailed Bethesda criteria and flow cytometry characteristics of 
murine tumors. Supplemental Tables 3, 4, and 5 show SNVs from 
exome sequencing of 3 Dnmt3a+/– tumors. Supplemental Table 6 
shows the VAFs of activated Ras mutations detected in AML samples. 
Supplemental Table 7 shows a list of all genes on the copy number–
altered regions of tumor E that may be relevant for AML pathogen-
esis. Supplemental Table 8 shows the locations of all significant DMRs 
detected between Dnmt3a+/+ and Dnmt3a–/– mice, with methylation 
values of the DMRs. Mean methylation values for the same DMRs are 
also shown for all Dnmt3a+/– samples by age of harvest. Supplemental 
Table 9 shows the average, median, and maximal number of sequenc-
ing reads from each of the genes used to assign cells to the myeloid 
lineage, for Dnmt3a+/+ (WT) versus Dnmt3a+/– (3a het) cells.
Statistics. All statistical comparisons were made using GraphPad 
Prism 5 software, except for statistics on sequencing data, which were 
calculated using the R statistical programming software as described 
above. Statistical tests employed and significance cut-offs are detailed 
in each figure legend. All data represent mean ±SD or SEM, as speci-
fied in figure legends.
Study approval. All mouse experiments were performed in accor-
dance with institutional guidelines and current NIH policies and were 
approved by the Animal Studies Committee of Washington University. 
All cryopreserved primary AML samples (TCGA ID nos. 2839, 2851, 
2879, 2993) were collected as part of a study approved by the Human 
Research Protection Office at Washington University School of Medi-
cine after patients provided informed consent in accordance with the 
Declaration of Helsinki.
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iants.R). The Dnmt3a locus was manually inspected for mutations, 
insertions, and deletions by displaying sequencing data in the Inte-
grated Genomics Viewer and subsequently analyzed for copy num-
ber changes using CopyCat2, which compares exome sequence 
against a pooled normal control for detection of CNVs (https://
github.com/abelhj/cc2/). Additional copy number analysis was 
performed using Varscan 2.3.6 (50) and segmented with the DNA-
copy package (54). Segments of less than 50 probes were filtered to 
remove noise, followed by merging of adjacent segments with abso-
lute copy number difference of less than 0.2. The Dnmt3a locus was 
manually reviewed for copy number alterations using both the raw 
and segmented data.
Exon array gene expression analysis. For expression array profil-
ing, total cellular RNA was purified using TRIzol reagent (Invitro-
gen), quantified using UV spectroscopy (Nanodrop Technologies), 
and qualitatively assessed using an Experion Bioanalyzer. Amplified 
cDNA was prepared from 20 ng total RNA using the whole transcript 
Ovation RNA Amplification System and biotin labeled using the 
Encore Biotin Module, both from NuGen Technologies, according to 
the manufacturer’s instructions. Labeled targets were then hybrid-
ized to Mouse Exon 1.0 ST arrays (Affymetrix), washed, stained, and 
scanned using standard protocols from the Siteman Cancer Center, 
Molecular and Genomic Analysis Core Facility (https://pathology.
wustl.edu/research/core-facilities/biomedical-informatics-cmbi/). 
Affymetrix Expression Console software was used to process array 
images, export signal data, and evaluate image and data quality rela-
tive to standard Affymetrix quality control metrics. Affymetrix CEL 
files were imported into Partek Genomics Suite 6.6 (Partek Inc.). 
Probe-level data were preprocessed, including background correc-
tion, normalization, and summarization, using robust multiarray 
average (RMA) analysis. RMA adjusts for background noise on each 
array using only perfect match (PM) probe intensities and subse-
quently normalizes data across all arrays using quantile normaliza-
tion (55, 56), followed by median polish summarization to generate a 
single measure of expression (56). Data were filtered to include only 
core probe sets having a raw expression signal greater than 200 in all 
samples in order to limit the analysis within well-annotated exons. 
The ANOVA and multi-test correction for P values in the Partek 
Genomics Suite were used to identify differentially expressed genes. 
Sample genotypes (Dnmt3a+/+, Dnmt3a+/–, Dnmt3a–/–) were chosen 
as the candidate variables in the ANOVA model to obtain genotype-
specific expression changes. ANOVA P values were corrected using 
Bonferroni’s method. The list of genes with significant variation in 
expression levels was generated on the basis of a fold change of 2 and 
a 0.05 FDR criterion as a significant cutoff. Data were deposited into 
the NCBI’s Gene Expression Omnibus (GEO GSE100702).
Supplemental figures. Supplemental Figure 1 shows Dnmt3a pro-
tein levels in Dnmt3a+/– mice. Supplemental Figure 2 shows normal 
hematopoiesis of young Dnmt3a+/– mice. Supplemental Figure 3 shows 
representative flow phenotyping of secondary tumors. Supplemental 
Figure 4 shows methylation data from a locus that is differentially 
methylated in both Dnmt3a–/– and Dnmt3a+/– bone marrow cells. 
Supplemental Figure 5 shows a representation of expression array 
data from the purified KLS cells of Dnmt3a+/+ versus Dnmt3a+/– cells. 
Supplemental Figure 6 shows the 10 k-means clusters overlaid on the 
t-SNE plot of the single cell RNA-seq from this study and the genes 
that are most differentially expressed within each cluster.
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